Transgenic mice having a human major histocompatibility complex (MHC) phenotype, experimental uses and applications
US9986721B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jul 17, 2012 |
| Grant date | Jun 5, 2018 |
| Priority date | — |
| Expiry date | Jan 23, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA01K2267/03
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted H2 class I gene, a disrupted H2 class II gene, a functional HLA class I transgene, and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cells are deficient for both H2 class I and class II molecules, wherein the transgenic mouse comprises a functional HLA class I transgene and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cell has the genotype HLA-A2+HLA-DR1+β2m°IAβ°. The invention also relates to methods of using a transgenic mouse of the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.